Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
113.25
+2.48 (2.24%)
Apr 3, 2025, 11:33 AM EDT - Market open
Novartis AG Revenue
In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth. Novartis AG had revenue of $13.56B in the quarter ending December 31, 2024, with 15.13% growth.
Revenue (ttm)
$51.72B
Revenue Growth
+10.85%
P/S Ratio
4.03
Revenue / Employee
$681,602
Employees
75,883
Market Cap
208.19B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
NVS News
- 5 hours ago - Pharma tariff relief likely short-lived with sector-specific duties on the horizon - CNBC
- 15 hours ago - Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) - PRNewsWire
- 15 hours ago - Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) - GlobeNewsWire
- 3 days ago - Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis - GlobeNewsWire
- 5 days ago - FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer - GlobeNewsWire
- 9 days ago - Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis - GlobeNewsWire
- 13 days ago - Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) - PRNewsWire
- 13 days ago - Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) - GlobeNewsWire